ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Mutations in the BAF SWI/SNF complex subunits are frequent in cancers but selective therapeutic approaches are not available yet. Here, the authors demonstrate that defects ofARID1Aand other subunits sensitizes cancer cells to the DNA checkpoint kinase inhibitor ATR in a synthetic lethal manner.

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Chris T. Williamson, Rowan Miller, Helen N. Pemberton, Samuel E. Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati, Colm J. Ryan, Jeff Francis, Peter B. Vermulen, Andrew R. Reynolds, Philip M. Reaper, John R. Pollard, Alan Ashworth, Christopher J. Lord
Format: article
Langue:EN
Publié: Nature Portfolio 2016
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/e641244f3cf24d9e87d1e6540b5b48bf
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:Mutations in the BAF SWI/SNF complex subunits are frequent in cancers but selective therapeutic approaches are not available yet. Here, the authors demonstrate that defects ofARID1Aand other subunits sensitizes cancer cells to the DNA checkpoint kinase inhibitor ATR in a synthetic lethal manner.

Documents similaires